Screening for Cross-Reactivity and Validation of Peptide-Centric CAR-T Cells for Neuroblastoma using MHC Dextramer®
Precision Immune Monitoring in Cell Therapy
Explore how Dextramer® reagents support the development and manufacturing of effective cell therapies.
Monitor Antigen Specificity
Specificity can be key to successful immune cell therapy. Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells for advanced cell therapy.
Reagents for Development and Manufacturing
Immudex is committed to providing sensitive Dextramer® reagents for precise detection, isolation, and validation of antigen-specific cells in cell therapy development and manufacturing.
Clinical Grade Reagents
Immudex provides high-quality GMP Dextramer® reagents that meet authoritative standards for production and manufacturing of cell therapy products.
Specificity can be Key to Successful Immune Cell Therapy
Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells.
Dextramer® technology can characterize and validate antigen-specific cell therapy products with high resolution during development, manufacturing, and release testing.
Develop and Manufacture Cell Therapies with Dextramer® Technology
- Epitope and neoepitope discovery
- TCR discovery, characterization, and validation including screening for TCR specificity and cross-reactivity
- Characterization and monitoring of antigen-specific cell therapy products in preclinical and clinical research
- Clinical-Grade (GMP) Dextramer® reagents for in-process control and release testing during manufacturing of cell therapy products
Explore Case Studies – Applications of Dextramer® Technology in Cell Therapy
Assessing the HLA-Specificity of CAR-T Cells with MHC I Dextramer® Reagents
Plasmacytoid Dendritic Cell Line-Based Vaccine Primes and Expands Antitumor T Cells in Melanoma Patients
A TCR-Accepting T-Cell Platform to Profile Tumor-Specific T-Cell Receptors
Identifying Shared Tumor Epitopes from Endogenous Retroviruses for High-Avidity Cytotoxic TILs using MHC Dextramer®
Cancer Neoepitopes for Immunotherapy: Strategies for Adoptive T-Cell Therapy
Identification of Epitopes that Pose as Attractive Targets for Vaccination and Other T-Cell Therapies with Klickmer®
Assessment of the safety and efficacy of a novel vaccine in high-grade glioma patients with Dextramer®
Exploring Neoantigen Cancer Vaccines in Combination with Immune Checkpoint Inhibitors Using MHC Dextramer®
Dextramer® Reagents Enable TCR Discovery
Immudex provides a range of ready-to-use, customizable, and peptide-receptive Dextramer® reagents enabling the discovery, characterization, and isolation of TCRs with therapeutic value across different platforms, including in-situ, flow cytometry, NGS, and single-cell multi‑omics.Download TCR Discovery Application Note
Immudex offers TCR Solutions providing Soluble TCR Monomers and TCR Dextramer® reagents to enable the quantification of Antigen-Presenting Cells, validation of TCR candidates, and other applications within CAR-T and TCR-T therapy.Discover TCR Solutions
Want to Hear More About Our Cell Therapy Solutions?
Fill in the form and one of our dedicated specialists will get in touch with you shortly